Abstract:Objective. There are generic fixed-dose combinations (FDCs) of ritonavir-boosted
darunavir (DRV/r) available in Argentina. Experiences with these FDCs in dual therapy
remain limited in clinical practice. We aimed to describe clinical and virologic
outcomes in patients exposed to FDC DRV/r + raltegravir (RAL) 400 mg every 12 h in a
real-life setting. Patients and methods. Retrospective analysis of electronic medical
records of HIV-infected patients und… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.